Cargando…
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Cancer is associated with higher morbidity and mortality and is the second leading cause of death in the US. Further, in some nations, cancer has overtaken heart disease as the leading cause of mortality. Identification of molecular mechanisms by which cancerous cells evade T cell-mediated cytotoxic...
Autores principales: | Vaddepally, Raju K., Kharel, Prakash, Pandey, Ramesh, Garje, Rohan, Chandra, Abhinav B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140028/ https://www.ncbi.nlm.nih.gov/pubmed/32245016 http://dx.doi.org/10.3390/cancers12030738 |
Ejemplares similares
-
PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020) -
Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
por: Vaddepally, Raju, et al.
Publicado: (2022) -
The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
por: Garje, Rohan, et al.
Publicado: (2020) -
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
por: Twomey, Julianne D., et al.
Publicado: (2021) -
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
por: Kurzrock, R, et al.
Publicado: (2019)